Gyre Therapeutics Shares Are Trading Higher After the Company Announced That China's NMPA Approved Avatrombopag Maleate Tablets for the Treatment of CLD-associated Thrombocytopenia.
Gyre Therapeutics Shares Are Trading Higher After the Company Announced That China's NMPA Approved Avatrombopag Maleate Tablets for the Treatment of CLD-associated Thrombocytopenia.
在该公司宣布中国国家药品监督管理局批准乙酰曲霉胺男ate片治疗CLD相关血小板减少症之后，Gyre Therapeutics股票价格上涨。
Gyre Therapeutics Shares Are Trading Higher After the Company Announced That China's NMPA Approved Avatrombopag Maleate Tablets for the Treatment of CLD-associated Thrombocytopenia.
在该公司宣布中国国家药品监督管理局批准乙酰曲霉胺男ate片治疗CLD相关血小板减少症之后，Gyre Therapeutics股票价格上涨。